Results
toxicity, non-NEN disease
ADVERSE EVENT
The assessment of adverse event rates for the first 20 patients showed that 75% needed dose reduction and 65% needed dose delay, but only three patients discontinued treatment due to toxicity. The interim analysis demonstrated a DCR of 90% at 6 weeks. Therefore, the study proceeded without adjustments to the study medication. From November 2014 to December 2017, 38 patients were recruited from seven centres in Denmark, Sweden, and Norway. One participant was excluded from further analysis during the enrolment period due to additional pathological information redefining the case as having non-NEN disease. The cut-off date for follow-up was August 17, 2021, where nine of 37 patients were still alive.